“Excellent scientific advice provided for the study design. Studies tailored for small biotechs with limited budget. Timelines met, rigor in execution. Indeed, a great partner for drug development in the metabolic disease area.”
Recent News
- Physiogenex to present the effects of semaglutide in aged pre-cirrhotic hamsters at the 10th Aging Research and Drug Discovery Meeting 08/29/2023
- Physiogenex to present a new diabetic NASH HFpEF hamster study at the 83rd American Diabetes Association meeting in San Diego, CA, USA, June 23-26, 2023 06/17/2023
- Physiogenex to present at the 1st T2D & Obesity Therapeutics Summit in Boston, MA, May 31 – June 1st, 2023 05/30/2023
- Physiogenex to attend Biomed Israël 2023 annual meeting in Tel Aviv, May 16 – May 18 05/11/2023
- Physiogenex and Vaiomer Launch the TRANSBIOTIC project: A New Collaborative Research Project on mouse models transplanted with Human Microbiome 05/11/2023
- Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference on Type 2 Diabetes therapeutics, May 1-4 in Palm Springs, CA, USA 04/19/2023